1. Market Research
  2. > Sarcomas - Pipeline Review, H1 2013

Sarcomas - Pipeline Review, H1 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 292 pages

Sarcomas – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Sarcomas - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Sarcomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sarcomas. Sarcomas - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Sarcomas.
- A review of the Sarcomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Sarcomas pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Sarcomas.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Sarcomas pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Sarcomas - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Sarcomas Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Sarcomas 10
Sarcomas Therapeutics under Development by Companies 12
Sarcomas Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Discovery and Pre-Clinical Stage Products 22
Comparative Analysis 22
Sarcomas Therapeutics - Products under Development by Companies 23
Sarcomas Therapeutics - Products under Investigation by Universities/Institutes 27
Companies Involved in Sarcomas Therapeutics Development 28
Bristol-Myers Squibb Company 28
Genzyme Corporation 29
Johnson and Johnson 30
F. Hoffmann-La Roche Ltd. 31
Shionogi and Co., Ltd. 32
Amgen Inc. 33
Sanofi-Aventis 34
Eli Lilly and Company 35
Merck and Co., Inc. 36
Gamida Cell Ltd. 37
Infinity Pharmaceuticals, Inc. 38
ZIOPHARM Oncology, Inc. 39
Novartis AG 40
Auxilium Pharmaceuticals, Inc. 41
Eisai Co., Ltd. 42
Pfizer Inc. 43
Cell Therapeutics, Inc. 44
Menarini Group 45
Alchemia Limited 46
EntreMed, Inc. 47
Celldex Therapeutics, Inc. 48
AEterna Zentaris Inc. 49
Marshall Edwards, Inc. 50
Oncolytics Biotech Inc. 51
ARQULE, INC 52
CytRx Corporation 53
Pharmacyclics, Inc. 54
Threshold Pharmaceuticals, Inc. 55
MabVax Therapeutics, Inc. 56
Nanobiotix 57
Morphotek, Inc. 58
PCI Biotech Holding ASA 59
Philogen S.p.A. 60
Vaccinex, Inc. 61
GP Pharm, S.A. 62
Neotropix, Inc. 63
Axelar AB 64
MolMed S.p.A. 65
PharmaMar, S.A. 66
Polaris Group 67
Epeius Biotechnologies Corporation 68
Sarcomas - Therapeutics Assessment 69
Assessment by Monotherapy Products 69
Assessment by Combination Products 70
Assessment by Route of Administration 71
Assessment by Molecule Type 73
Drug Profiles 76
perifosine - Drug Profile 76
eribulin mesylate - Drug Profile 79
eribulin mesylate - Drug Profile 83
brivanib alaninate - Drug Profile 87
sabarubicin - Drug Profile 90
olaratumab - Drug Profile 92
axitinib - Drug Profile 94
cixutumumab - Drug Profile 97
Fibromun - Drug Profile 100
retaspimycin hydrochloride - Drug Profile 101
collagenase clostridium histolyticum - Drug Profile 104
brostallicin - Drug Profile 107
doxorubicin - Drug Profile 109
CDX-1401 - Drug Profile 110
ridaforolimus - Drug Profile 112
ridaforolimus - Drug Profile 116
abexinostat hydrochloride - Drug Profile 120
ENMD-2076 - Drug Profile 122
panobinostat - Drug Profile 124
PC-A11 + [bleomycin sulfate] - Drug Profile 129
NTX-010 - Drug Profile 131
ganitumab - Drug Profile 133
aldoxorubicin - Drug Profile 136
iniparib - Drug Profile 138
NGR-hTNF - Drug Profile 140
AXL-1717 - Drug Profile 143
pracinostat - Drug Profile 145
Reolysin - Drug Profile 147
TH-302 - Drug Profile 151
MORAb-004 - Drug Profile 158
RG-7112 - Drug Profile 160
tivantinib - Drug Profile 162
PM-00104 - Drug Profile 165
NBTXR-3 - Drug Profile 166
Rexin-G - Drug Profile 168
X-396 - Drug Profile 170
X-379 - Drug Profile 171
ADI-PEG 20 - Drug Profile 172
palifosfamide + [doxorubicin] - Drug Profile 175
Reolysin + [cisplatin] + Radiation Therapy - Drug Profile 177
CDX-1401 + [resiquimod] - Drug Profile 179
trabectedin + [doxorubicin liposomal] - Drug Profile 180
TH-302 + [doxorubicin] - Drug Profile 181
conatumumab + [doxorubicin] - Drug Profile 183
Sarcoma Vaccine - Drug Profile 184
plerixafor - Drug Profile 185
trabectedin - Drug Profile 187
trabectedin - Drug Profile 190
LY-2940680 - Drug Profile 193
VX-70 - Drug Profile 194
TNF-PEG 20 - Drug Profile 195
doxorubicin Second Generation - Drug Profile 196
Drug Targeting Natural Killer Cells - Drug Profile 197
TriN-2755 - Drug Profile 199
1-B7 - Drug Profile 201
Autologous T Cells Expressing Enhanced TCRs Specific For NY-ESO-1 and LAGE-1 - Drug Profile 202
EC-8042 - Drug Profile 204
doxorubicin Liposomal - Drug Profile 206
CBI-101 - Drug Profile 207
SP-2509 - Drug Profile 208
MN-4 - Drug Profile 209
Peptide Cocktail Vaccine - Drug Profile 210
NBTX-TOPO - Drug Profile 211
Sarcomas Therapeutics - Drug Profile Updates 212
Sarcomas Therapeutics - Discontinued Products 274
Sarcomas Therapeutics - Dormant Products 275
Sarcomas - Product Development Milestones 279
Featured News and Press Releases 279
Appendix 287
Methodology 287
Coverage 287
Secondary Research 287
Primary Research 287
Expert Panel Validation 287
Contact Us 288
Disclaimer 288



List of Tables

Number of Products Under Development for Sarcomas, H1 2013 14
Products under Development for Sarcomas - Comparative Analysis, H1 2013 15
Number of Products under Development by Companies, H1 2013 17
Number of Products under Development by Companies, H1 2013 (Contd..1) 18
Number of Products under Development by Companies, H1 2013 (Contd..2) 19
Number of Products under Development by Companies, H1 2013 (Contd..3) 20
Number of Products under Investigation by Universities/Institutes, H1 2013 22
Comparative Analysis by Late Stage Development, H1 2013 23
Comparative Analysis by Mid Clinical Stage Development, H1 2013 24
Comparative Analysis by Early Clinical Stage Development, H1 2013 25
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 26
Products under Development by Companies, H1 2013 27
Products under Development by Companies, H1 2013 (Contd..1) 28
Products under Development by Companies, H1 2013 (Contd..2) 29
Products under Development by Companies, H1 2013 (Contd..3) 30
Products under Investigation by Universities/Institutes, H1 2013 31
Bristol-Myers Squibb Company, H1 2013 32
Johnson and Johnson, H1 2013 34
F. Hoffmann-La Roche Ltd., H1 2013 35
Shionogi and Co., Ltd., H1 2013 36
Amgen Inc., H1 2013 37
Sanofi-Aventis, H1 2013 38
Eli Lilly and Company, H1 2013 39
Merck and Co., Inc., H1 2013 40
Infinity Pharmaceuticals, Inc., H1 2013 42
ZIOPHARM Oncology, Inc., H1 2013 43
Novartis AG, H1 2013 44
Auxilium Pharmaceuticals, Inc., H1 2013 45
Eisai Co., Ltd., H1 2013 46
Pfizer Inc., H1 2013 47
Cell Therapeutics, Inc., H1 2013 48
Menarini Group, H1 2013 49
EntreMed, Inc., H1 2013 51
Celldex Therapeutics, Inc., H1 2013 52
AEterna Zentaris Inc., H1 2013 53
Marshall Edwards, Inc., H1 2013 54
Oncolytics Biotech Inc., H1 2013 55
ARQULE, INC, H1 2013 56
CytRx Corporation, H1 2013 57
Threshold Pharmaceuticals, Inc., H1 2013 59
MabVax Therapeutics, Inc., H1 2013 60
Nanobiotix, H1 2013 61
Morphotek, Inc., H1 2013 62
PCI Biotech Holding ASA, H1 2013 63
Philogen S.p.A., H1 2013 64
Vaccinex, Inc., H1 2013 65
GP Pharm, S.A., H1 2013 66
Neotropix, Inc., H1 2013 67
Axelar AB, H1 2013 68
MolMed S.p.A., H1 2013 69
PharmaMar, S.A., H1 2013 70
Polaris Group, H1 2013 71
Epeius Biotechnologies Corporation, H1 2013 72
Assessment by Monotherapy Products, H1 2013 73
Assessment by Combination Products, H1 2013 74
Assessment by Stage and Route of Administration, H1 2013 76
Assessment by Stage and Molecule Type, H1 2013 79
Sarcomas Therapeutics - Drug Profile Updates 216
Sarcomas Therapeutics - Discontinued Products 278
Sarcomas Therapeutics - Dormant Products 279
Sarcomas Therapeutics - Dormant Products (Contd..1) 280
Sarcomas Therapeutics - Dormant Products (Contd..2) 281
Sarcomas Therapeutics - Dormant Products (Contd..3) 282



List of Figures

Number of Products under Development for Sarcomas, H1 2013 14
Products under Development for Sarcomas - Comparative Analysis, H1 2013 15
Products under Development by Companies, H1 2013 16
Products under Investigation by Universities/Institutes, H1 2013 21
Late Stage Products, H1 2013 23
Mid Clinical Stage Products, H1 2013 24
Early Clinical Stage Products, H1 2013 25
Discovery and Pre-Clinical Stage Products, H1 2013 26
Assessment by Monotherapy Products, H1 2013 73
Assessment by Combination Products, H1 2013 74
Assessment by Route of Administration, H1 2013 75
Assessment by Stage and Route of Administration, H1 2013 76
Assessment by Molecule Type, H1 2013 77
Assessment by Stage and Molecule Type, H1 2013 78

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.